VivoSeq
Other

Skin Lesions

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Skin Lesions is an early-stage landscape with 0 programs across 3 companies. The most active players are Atlas Molecular Pharma, Sun Pharmaceutical Industries, Inc., Nobelpharma.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Atlas Molecular Pharma

0 programs

PreclinicalSun Pharmaceutical Industries, Inc. logo

Sun Pharmaceutical Industries, Inc.

0 programs

PreclinicalN

Nobelpharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Withdrawn1 · 14%
Terminated1 · 14%
Recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
Recruiting·AAtlas Molecular Pharma·Phase 1/2·NCT07024316·6 enrolled
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT03629379·20 enrolled
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
Completed·AAIDS Malignancy Consortium·Phase 3·NCT02059499·91 enrolled
A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.
Completed·Sun Pharmaceutical Industries, Inc. logoSun Pharmaceutical Industries, Inc.·Phase 1·NCT01876550·1,902 enrolled
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
Completed·NNobelpharma·Phase 3·NCT05495425·43 enrolled
Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2
Terminated·—·Phase 3·NCT03233828·1 enrolled
Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions
Withdrawn·NNorthwestern University·Phase 1·NCT01735942

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)